TPP-1 formulations and methods for treating CLN2 disease
Formulations comprising recombinant human tripeptidyl peptidase-1 (rhTPP1) for intrathecal, intracerebroventricular, or intraocular administration, and kits comprising the same, are disclosed. Methods of using rhTPP1 in the prevention and treatment of symptoms of Neuronal Ceroid Lipofuscinosis (CLN2) disease are also disclosed. The formulations and methods are effective in halting the progression of CLN2 disease and may be used to treat subjects having CLN2 or a family history of CLN2.
1. A method of treating Neuronal Ceroid Lipofuscinosis (CLN2) disease comprising administering i) about 10 mL of a composition comprising a dose of about 300 mg of recombinant human tripeptidyl peptidase-1 (rhTPP1) to a subject in need thereof, wherein the composition is administered to the subject over a period of about 4 hours, or ii) administering a rhTPP1 composition to a subject in need thereof at a dose of about 300 mg, wherein the dose is administered to the subject at a rate less than or equal to 75 mg/2.5 mL/hour and wherein the composition has a pH of 6.5 and the rhTPP1 is not aggregated.
2. A method of preventing symptoms of Neuronal Ceroid Lipofuscinosis (CLN2) disease comprising
i) administering about 10 mL of a composition comprising a dose of about 300 mg of recombinant human tripeptidyl peptidase-1 (rhTPP1) to a subject in need thereof, wherein the composition is administered to the subject over a period of about 4 hours; ii) administering a rhTPP1 composition to a subject in need thereof at a dose of about 300 mg, wherein the dose is administered to the subject at a rate less than or equal to 75 mg/hour; or
iii) administering a rhTPP1 composition to a subject in need thereof at a dose of about 300 mg, wherein the dose is administered to the subject at a rate less than or equal to 75 mg/2.5 mL/hour and wherein the composition has a pH of 6.5 and the rhTPP1 is not aggregated.
3. The method of claim 2 , wherein the formulation, composition or dose is administered intracerebroventricularly, intrathecally, intraocularly, intracerebroventricularly and intraocularly, or intrathecally and intraocularly.
4. A method of treating Neuronal Ceroid Lipofuscinosis (CLN2) disease comprising administering a composition comprising rhTPP1 to a subject in need thereof at a dose of rhTPP1 effective to maintain a physiological function or slow or reduce deterioration of a physiological function in the subject, wherein the physiological function is language function, motor function, vision or feeding function, wherein the composition comprises rhTPP1 at a concentration of from about 25 mg/mL to about 35 mq/mL, further comprising potassium chloride at a concentration of about 0.01 mg/mL to about 1 mg/mL, magnesium chloride hexahydrate at a concentration of about 0.01 mg/mL to about 1 mg/mL, and calcium chloride dehydrate at a concentration of about 0.01 mg/m L to about 1 mq/m L and wherein the composition has a pH of 6.5 and the rhTPP1 is not aggregated.
5. The method of claim 4 , wherein the dose of rhTTP1 i) is effective to maintain language function or slow or reduce deterioration of language function in the subject; and/or ii) is effective to maintain motor function or slow or reduce deterioration of motor function in the subject.
6. The method of claim 4 , wherein the dose is i) about 10 mL of a composition comprising about 300 mg of rhTPP1 administered to the subject over a period of about 4 hours; ii) about 300 mg of rhTPP1 administered to the subject at a rate less than or equal to about 75 mg/hr; or iii) about 300 MCI of rhTPP1 administered to the subject at a rate less than or equal to about 75 mg/2.5 mL/hour.
7. The method of claim 4 , wherein the dose is administered every other week.
8. The method of claim 4 , wherein the dose is administered intracerebroventricularly, intrathecally, intraocularly, intracerebroventricularly and intraocularly.
9. The method of claim 4 , wherein the dose is administered in a formulation comprising sodium phosphate dibasic heptahydrate at a concentration of about 0.01 mg/mL to about 1 mg/mL, sodium phosphate monobasic monohydrate at a concentration of about 0.01 mg/mL to about 1 mg/mL, and sodium chloride at a concentration of about 1 mg/mL to about 20 mg/mL.
10. The method of claim 4 , wherein the dose is administered in a formulation comprising sodium phosphate dibasic heptahydrate at a concentration of about 0.11 mg/mL, sodium phosphate monobasic monohydrate at a concentration of about 0.08 mg/mL, sodium chloride at a concentration of about 8.77 mg/mL, potassium chloride at a concentration of about 0.22 mg/mL, magnesium chloride hexahydrate at a concentration of about 0.16 mg/mL, and calcium chloride dihydrate at a concentration of about 0.21 mg/mL.
11. A method of maintaining vision or slowing or reducing deterioration of vision in a subject having Neuronal Ceroid Lipofuscinosis (CLN2) disease comprising administering a therapeutically effective dose of rhTPP1 to the subject wherein the composition comprises rhTPP1 at a concentration of from about 25 mg/mL to about 35 mg/mL, further comprising potassium chloride at a concentration of about 0.01 mg/mL to about 1 mg/mL, magnesium chloride hexahydrate at a concentration of about 0.01 mg/mL to about 1 mg/mL, and calcium chloride dehydrate at a concentration of about 0.01 mg/mL to about 1 mg/mL, and wherein the composition has a pH of 6.5 and the rhTPP1 is not aggregated.
12. A method of treating Neuronal Ceroid Lipofuscinosis (CLN2) disease comprising administering a composition comprising rhTPP1 to a subject in need thereof at a dose effective to improve physiological function in the subject, wherein the physiological function is language function, motor function, vision or feeding function, wherein the composition comprises rhTPP1 at a concentration of from about 25 mg/mL to about 35 mg/mL, further comprising potassium chloride at a concentration of about 0.01 mg/mL to about 1 mg/mL, magnesium chloride hexahydrate at a concentration of about 0.01 mg/mL to about 1 mg/mL, and calcium chloride dehydrate at a concentration of about 0.01 mg/mL to about 1 mg/mL, and wherein the composition has a pH of 6.5 and the rhTPP1 is not aggregated.
13. The method of claim 12 , wherein the dose of rhTPP1 is effective to provide an improvement in vision.
14. The method of claim 13 , wherein the improvement in vision is an increase equal to or more than one point as measured using a Hamburg disease rating scale.
15. A method of improving language function and/or motor function in a subject having Neuronal Ceroid Lipofuscinosis (CLN2) disease, comprising administering a composition comprising a therapeutically effective dose of rhTPP1 to the subject, wherein the composition comprises rhTPP1 at a concentration of from about 25 mg/mL to about 35 mg/mL, further comprising potassium chloride at a concentration of about 0.01 mg/mL to about 1 mg/mL, magnesium chloride hexahydrate at a concentration of about 0.01 mg/mL to about 1 mg/mL, and calcium chloride dehydrate at a concentration of about 0.01 mg/mL to about 1 mg/mL, and wherein the composition has a pH of 6.5 and the rhTPP1 is not aggregated.
16. A method of treating Neuronal Ceroid Lipofuscinosis (CLN2) disease comprising administering a composition comprising rhTPP1 to a subject in need thereof at a dose effective to prevent or improve a neurological symptom of the disease, wherein the neurological symptom is a decrease in brain volume, a decrease in gray matter in the brain, a seizure, or an increase in cranial cerebrospinal fluid, wherein the composition comprises rhTPP1 at a concentration of from about 25 mg/mL to about 35 mg/m L, further comprising potassium chloride at a concentration of about 0.01 mg/mL to about 1 mg/mL, magnesium chloride hexahydrate at a concentration of about 0.01 mg/mL to about 1 mg/mL, and calcium chloride dehydrate at a concentration of about 0.01 mg/mL to about 1 mg/mL and wherein the composition has a pH of 6.5 and the rhTPP1 is not aggregated.
17. The method of claim 16 , wherein the dose of rhTPP1 is effective to i) maintain grey matter or slow or reduce deterioration of gray matter in the brain of the subject; ii) reduce the number of seizures per month that the subject experiences; and/or iii) maintain the volume of cranial cerebrospinal fluid or slow the increase in the volume of cranial cerebrospinal fluid in the subject.
18. A method of maintaining brain volume or slowing or reducing a decrease in brain volume in a subject having Neuronal Ceroid Lipofuscinosis (CLN2) disease, comprising administering a composition comprising a therapeutically effective dose of rhTPP1 to the subject, wherein the composition comprises rhTPP1 at a concentration of from about 25 mg/mL to about 35 mg/mL, further comprising potassium chloride at a concentration of about 0.01 mg/mL to about 1 mg/mL, magnesium chloride hexahydrate at a concentration of about 0.01 mg/mL to about 1 mg/mL, and calcium chloride dehydrate at a concentration of about 0.01 mg/mL to about 1 mg/mL, and wherein the composition has a pH of 6.5 and the rhTPP1 is not aggregated.